H&R GmbH & Co. KGaA Releases Preliminary Nine-Month Figures for 2024

H&R GmbH & Co. KGaA, based in Salzbergen, Germany, reported sales exceeding EUR 1 billion for the nine-month period of 2024. EBITDA stabilized at EUR 65.9 million, matching the previous year's figure of EUR 66.6 million. Notably, the third quarter showed the strongest momentum with EBITDA reaching EUR 24.8 million, although slightly below the EUR 27.2 million reported in Q3 2023.

The ChemPharm REFINING segment was the main contributor this year, despite a weaker third-quarter performance compared to 2023. International operations in ChemPharm SALES showed recovery, with a quarterly operating result of EUR 9.7 million.

Operating cash flow weakened to EUR 53.8 million over nine months but improved significantly in Q3 2024 to EUR 48.3 million. Total assets reached EUR 943.6 million by September 30, 2024. The company anticipates comparable results to the previous year, with final figures due on November 14, 2024.